Sorry, you need to enable JavaScript to visit this website.
Skip to main content
 

Search

Heather L Davis, Ph.D.

HEATHER L DAVIS, PH.D.

Vice President, R&D
DAS Leader, Hepatitis

As Disease Area Stronghold R&D Leader for Hepatitis, Heather Davis, Ph.D., leads the Hepatitis team to advance their goal of transforming disease management and outcomes for patients who are chronically infected with the hepatitis B virus (HBV). Heather is deeply committed to developing innovative treatment options that will help to alleviate the burden of HBV in populations around the world.

Prior to joining the Johnson & Johnson Family of Companies, Heather was Head of R&D Portfolio and Program Management for Seqirus, a company developing influenza vaccines. Previously, she worked for Pfizer as Executive Director in Vaccine R&D and Site Head, with responsibility for all Canadian R&D activities including animal pharmacology studies, clinical assay development and conduction, as well as Program Lead for two global therapeutic vaccine programs that she led from early discovery through Phase 1 testing.

Heather was also a scientific co-founder of Coley Pharmaceutical Group, a biotechnology company developing CpG oligonucleotides (TLR9 agonists) as vaccine adjuvants and immune modulators in infectious disease and oncology. While at Coley, she led R&D efforts in both hepatitis B (vaccines) and hepatitis C (immune therapy). Before this, Heather worked in academia, first at McGill University Faculty of Medicine (Montreal), and then at the University of Ottawa – during this time, she was a pioneer in the field of DNA vaccines, developing the first DNA vaccine for HBV.

Heather received her Ph.D. from the University of Western Ontario and did post-doctoral and sabbatical work at the University of British Columbia (Vancouver) and the Pasteur Institute (Paris). Over her career, Heather has authored 116 peer-reviewed manuscripts and is the inventor on 13 patent families.

Read more: